Those sizeable U.K. offerings

In an IPO market where many U.S. biotech companies are taking haircuts on their road shows, U.K.-based Cambridge Antibody Technology managed to raise £41.3 million (US$66 million). To provide a parallel, on Friday Cell Therapeutics (CTIC) - a U.S. biotech company with a cancer product in Phase III trials - sold its 3 million-share IPO at $10. CTIC had hoped to sell the shares at $14-$16. More generally, the eight U.S. IPOs completed this year raised from $14 million to $62 million each, for an average of $30 million per offering.

Ebb & Flow asked some U.K. investors why their brethren are so generous.

One key is the small pool of publicly held biotech companies in which to

Read the full 1163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE